Cannabis Bioscience International Holdings, Inc. (OTC: CBIH)

Cannabis Bioscience International Holdings, Inc. operates in the cannabis biotechnology sector, focusing on research, education, and clinical trial services. The company runs three distinct businesses: Pharmacology University provides cannabis‑related education and training; Alpha Research Institute conducts clinical trials for sponsors and contract research organizations; and the CBD Business aims to develop, manufacture and market cannabinoid‑based wellness products under the VitaCookies brand. These activities place the firm at the intersection of scientific research and the growing medical cannabis industry.

The company generates revenue primarily from educational services delivered through Pharmacology University, clinical trial and consulting fees earned by Alpha Research, and anticipates future income from the sale of CBD products. Currently, revenue stems from continuing medical education courses, certification programs, and clinical trial sponsorships, with no significant sales from the CBD line as it remains in the pre‑launch phase.

The company operates through the following segments:

• Pharmacology University Business: This segment offers continuing medical and legal education, certification courses, general seminars, on‑site training and digital products such as e‑books, audiobooks and video courses to professionals, students and others interested in the cannabis industry.

• Alpha Research Business: This segment provides clinical trial services as a sponsor and contract research organization, managing study design, patient recruitment, regulatory compliance and data reporting across multiple therapeutic areas for pharmaceutical and biotech clients.

• CBD Business: This segment plans to formulate, manufacture and market functional wellness edibles under the VitaCookies brand, targeting specific health conditions such as chronic pain, menopause and anxiety through cannabinoid‑infused food products.

Within the cannabis biotechnology niche, Cannabis Bioscience International Holdings, Inc. differentiates itself by combining scientific research with educational outreach, maintaining a modest but growing intellectual property portfolio that includes ten patent applications and numerous formulations. While larger pharmaceutical companies dominate clinical development, the firm leverages its agility, law‑enforcement collaborations and specialized expertise in cannabis‑focused training to carve out a defensible position.

The company’s customer base includes pharmaceutical sponsors such as Pfizer Inc., Merck & Co., Inc., Shionogi & Co., Ltd., Medtronic plc, Novartis, GlaxoSmithKline plc, Gilead Sciences, Inc. and Johnson & Johnson, as well as contract research organizations like PPD, Inc., Icon plc, Parexel, PRA Health Sciences, Inc., Covance, IQVIA Holdings Inc. and Medpace Holdings, Inc. Pharmacology University serves healthcare professionals, educators, industry workers and students through partnerships with institutions such as Jorge Tadeo Lozano University, Clayton State University and the Polytechnic University of Puerto Rico. The planned CBD Business will initially target patients and wellness consumers in Texas.